Examples of New Merck in a sentence
No. of Projects % of Sales 2005 estimated R&D budgets (€m) of select mid- size pharmaceuticals companies Eli Lilly Wyeth Bristol Myers Boehringer New Merck Group1 Schering-Plough Takeda Schering AG1 Bayer Novo Nordisk UCB Merck KGaA Organon Forest Shire a 2436 2059 1818 1320 1127 1059 743 682 483 434 236 225 b 1302 c 860 d 442 19.3% 23.1% 18.5% 14.8% 22.0% 19.0% 15.1% 21.1% 25.7% 17.9% 9.4% 17.8% 12 30 20 18 19 22 17 10 11 13 11 7 14.8% 26 17.9% 39 22.0% 29 Excluding Diagnostic Imaging.
As a result of the merger, New Merck acquired the non-controlling interest in the Merck/Schering-Plough cholesterol partnership and therefore obtained a controlling interest in the Merck/Schering-Plough cholesterol partnership.
In the event that any of those governmental entities believes that wrongdoing has occurred, one or more of them could institute civil or criminal proceedings which, if resolved unfavorably, could subject Merck or Schering-Plough, or New Merck after completion of the merger, to substantial fines, penalties and injunctive or administrative remedies, including exclusion from government reimbursement programs.
For example, the merger agreement provides that three directors of Schering-Plough will become directors of New Merck after the merger.
If a Merck shareholder acquired different blocks of Merck shares at different times or at different prices, the shareholder's tax basis and holding period in the shares of New Merck common stock received in the Merck merger may be determined with reference to each block of shares of Merck common stock.
In general, both Merck and Schering-Plough face increasing competition from lower-cost generic products and New Merck will face the same challenge after the merger.
The aggregate tax basis of the shares of New Merck common stock received in the Merck merger generally will be equal to the aggregate tax basis in the shares of Merck common stock surrendered.
The table below shows the market values of the investment portfolio by asset class as at 31 December 2021 and 31 December 2020.
The aggregate tax basis of the shares of New Merck common stock received in the Schering- Plough merger generally will be equal to the adjusted tax basis in the shares of Schering-Plough common stock exchanged, less the adjusted tax basis allocated to the portion of the shares of Schering-Plough common stock exchanged for cash in the Schering-Plough merger.
Fluctuations in the share price of Merck, or New Merck following the merger, could result from changes in the business, operations or prospects of Merck or Schering-Plough prior to the merger or New Merck following the merger, regulatory considerations, general market and economic conditions and other factors both within and beyond the control of Merck or Schering-Plough.